Extended Data Fig. 5: Sankey Diagrams showing the ctDNA dynamics and relation with outcome. | Nature Medicine

Extended Data Fig. 5: Sankey Diagrams showing the ctDNA dynamics and relation with outcome.

From: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Extended Data Fig. 5

Top: ctDNA in urine in patients in cohort 1 (n=24). Bottom: ctDNA in plasma in patients in cohort 1 and 2 combined (n=41). Red, blue and grey bars represent the number of patients with detectable, undetectable or missing ctDNA measurements, respectively, at different timepoints (Baseline, Pre-C2, Pre-C3 or Pre-surgery). In follow-up, red and blue bars represent the number of patients with and without disease progression, respectively. Pre-C2/3: prior to second or third treatment cycle.

Back to article page